Consensus recommendations for standard investigative workup: Report of the International Myeloma Workshop Consensus Panel 3

Blood

Volumn 117, Issue 18, 2011, Pages 4701-4705

  Dimopoulos, Meletios ^a   Kyle, Robert ^b   Fermand, Jean Paul ^c   Rajkumar, S Vincent ^b   San Miguel, Jesus ^d   Chanan Khan, Asher ^e   Ludwig, Heinz ^f   Joshua, Douglas ^g   Mehta, Jayesh ^h   Gertz, Morie ^b   Avet Loiseau, Hervé ⁱ   Beksaç, Meral ^j   Anderson, Kenneth C ^k   Moreau, Philippe ⁱ   Singhal, Seema ^h   Goldschmidt, Hartmut ^l   Boccadoro, Mario ^m   Kumar, Shaji ^b   Giralt, Sergio ⁿ   Munshi, Nikhil C ^k,o   Jagannath, Sundar ^p   more..

^a UNIVERSITY OF ATHENS   (Greece)

^b MAYO CLINIC   (United States)

^c SAINT LOUIS HOSPITAL   (France)

^d UNIVERSITY OF SALAMANCA   (Spain)

^e ROSWELL PARK CANCER INSTITUTE   (United States)

^f WILHELMINEN HOSPITAL   (Austria)

^g Bosch Institute   (Australia)

^h NORTHWESTERN UNIVERSITY   (United States)

ⁱ UNIVERSITÉ DE NANTES   (France)

^j ANKARA UNIVERSITY   (Turkey)

^k DANA FARBER CANCER INSTITUTE   (United States)

^l UNIVERSITY OF HEIDELBERG   (Germany)

^m UNIVERSITY OF TURIN   (Italy)

ⁿ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^o VA BOSTON HEALTHCARE SYSTEM   (United States)

^p MOUNT SINAI SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; LACTATE DEHYDROGENASE;

BLOOD SAMPLING; BONE MARROW BIOPSY; CANCER SCREENING; CHROMOSOME 17P; CLONAL VARIATION; CONFERENCE PAPER; CYTOGENETICS; DENSITOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; LABORATORY TEST; METAPHASE; MULTIPLE MYELOMA; NEPHELOMETRY; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMA CELL; PLASMA CELL DYSCRASIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; URINALYSIS;

EID: 79956001465     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-10-299529     Document Type: Conference Paper

References (29)

1. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749-757.
2. Smith A, Wisloff F, Samson D. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol. 2006;132(4):410-451.
3. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23(1):3-9.
4. Kyle RA. Sequence of testing for monoclonal gammopathies: serum and urine assays. Arch Pathol Lab Med. 1999;123(2):114-118. (Pubitemid 29093595)
5. Riches PG, Sheldon J, Smith AM, et al. Overestimation of monoclonal immunoglobulin by immunochemical methods. Ann Clin Biochem. 1991; 28(3):253-259.
6. Greipp PR, San Miguel JF, Durie BG, et al. International Staging System for multiple myeloma. J Clin Oncol. 2005;23(15):3412-3420.
7. Snozek CL, Saenger AK, Greipp PR, et al. Comparison of bromcresol green and agarose protein electrophoresis for quantitation of serum albumin in multiple myeloma. Clin Chem. 2007;53(6): 1099-1103. (Pubitemid 46867526)
8. Kapoor P, Snozek CL, Colby C, et al. Clinical impact of discordance in serum albumin measurements on multiple myeloma International Staging System. J Clin Oncol. 2008;26(24):4051-4052.
9. Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chain. Clin Chem. 2002;48(9):1437-1444. (Pubitemid 34925779)
10. Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum- free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009;23(2):215-224.
11. Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR. Serum free light chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood. 2001;97(9):2900-2902.
12. Dingli D, Kyle RA, Rajkumar SV, et al. Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood. 2006;108(6):1979-1983. (Pubitemid 44395010)
13. Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008; 111(2):785-789.
14. Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light ration is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005;106(3): 812-817. (Pubitemid 41076419)
15. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351(18):1860-1873.
16. Rajkumar SV, Fonseca R, Dispenzieri A, et al. Methods for estimation of bone marrow plasma cell involvement in myeloma: predictive value for response and survival in patients undergoing autologous stem cell transplantation. Am J Hematol. 2001;68(4):269-275. (Pubitemid 33108430)
17. Avet-Loiseau H. Role of genetics in prognostication in myeloma. Best Pract Res Clin Haematol. 2007;20(4):625-635. (Pubitemid 350225352)
18. Dimopoulos MA, Barlogie B, Smith TL, Alexanian R. High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med. 1991;115(12):931-935.
19. Moulopoulos LA, Dimopoulos MA, Alexanian R, Leeds NE, Libshitz HI. Multiple myeloma: MR patterns of response to treatment. Radiology. 1994;193(2):441-446. (Pubitemid 24338331)
20. Moulopoulos LA, Dimopoulos MA, Weber D, et al. Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. J Clin Oncol. 1993;11(7):1311-1315. (Pubitemid 23199135)
21. Moulopoulos LA, Dimopoulos MA, Smith TL, et al. Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol. 1995;13(1):251-256.
22. Mariette X, Zagdanski AM, Guermazi A, et al. Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma. Br J Haematol. 1999; 104(4):723-729. (Pubitemid 29143489)
23. Baur-Melnyk A, Buhmann S, Durr HR, Reiser M. Role of MRI for the diagnosis and prognosis of multiple myeloma. Eur J Radiol. 2005;55(1):56-63. (Pubitemid 40798488)
24. Moulopoulos LA, Gika D, Anagnostopoulos A, et al. Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma. Ann Oncol. 2005; 16(11):1824-1828. (Pubitemid 41631247)
25. Walker R, Barlogie B, Haessler J, et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol. 2007; 25(9):1121-1128. (Pubitemid 46596765)
26. Durie BG,WaxmanAD, D'Angolo A, Williams CM. Whole-body FDG PET identifies high-risk myeloma. J Nucl Med. 2002;43(11):1457-1463. (Pubitemid 35285870)
27. Zamagni E, Nanni C, Patriarca F, et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and wholebody planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica. 2007;92(1):50-55. (Pubitemid 46232657)
28. Bartel TB, Haessler J, Brow TLY, et al. F-18 fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009; 114(10):2068-2076.
29. Salaun PY, Gastinne T, Frampas E, Bodet-Milin C, Moreau P, Bodéré-Kraeber F. FDG-positron-emission tomography for staging and therapeutic assessment in patients with plasmacytoma. Haematologica. 2008;93(8):1269-1271.